IMMUCELL CORP (ICCC) Stock Price & Overview
NASDAQ:ICCC • US4525253062
Current stock price
The current stock price of ICCC is 6.44 USD. Today ICCC is up by 1.42%. In the past month the price increased by 1.42%. In the past year, price increased by 20.15%.
ICCC Key Statistics
- Market Cap
- 58.282M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.11
- Dividend Yield
- N/A
ICCC Stock Performance
ICCC Stock Chart
ICCC Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ICCC. When comparing the yearly performance of all stocks, ICCC turns out to be only a medium performer in the overall market: it outperformed 66.7% of all stocks.
ICCC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ICCC. ICCC has an average financial health and profitability rating.
ICCC Earnings
On March 4, 2026 ICCC reported an EPS of -0.31 and a revenue of 7.63M.
ICCC Forecast & Estimates
ICCC Groups
Sector & Classification
ICCC Financial Highlights
Over the last trailing twelve months ICCC reported a non-GAAP Earnings per Share(EPS) of -0.11. The EPS increased by 62.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.37% | ||
| ROA | 5.08% | ||
| ROE | 7.8% | ||
| Debt/Equity | 0.27 |
ICCC Ownership
ICCC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ICCC
Company Profile
ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine. The firm is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. The company operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Company Info
IPO: 1987-05-01
IMMUCELL CORP
56 Evergreen Drive
Portland MAINE 04103 US
CEO: Michael F. Brigham
Employees: 72
Phone: 12078782770
IMMUCELL CORP / ICCC FAQ
Can you describe the business of IMMUCELL CORP?
ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine. The firm is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. The company operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
What is the stock price of IMMUCELL CORP today?
The current stock price of ICCC is 6.44 USD. The price increased by 1.42% in the last trading session.
Does ICCC stock pay dividends?
ICCC does not pay a dividend.
What is the ChartMill rating of IMMUCELL CORP stock?
ICCC has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How many employees does IMMUCELL CORP have?
IMMUCELL CORP (ICCC) currently has 72 employees.
What is the market capitalization of ICCC stock?
IMMUCELL CORP (ICCC) has a market capitalization of 58.28M USD. This makes ICCC a Micro Cap stock.
Can you provide the ownership details for ICCC stock?
You can find the ownership structure of IMMUCELL CORP (ICCC) on the Ownership tab.